Home›Trial›NCT06335979
🔬NCT06335979Phase 1RECRUITING

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

Study Summary

The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565 in participants with SLE

Conditions
Systemic Lupus Erythematosus, SLE
Interventions / Drugs
PIT565
View on ClinicalTrials.gov ↗
Sponsor
NVS
Novartis AG
Diversified Pharma
D36/100
Study Details
Enrollment54 participants
Primary Completion—
Lead SponsorNovartis Pharmaceuticals
Data Retrieved2026-04-11 02:55:49.151297+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.